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Objectives: Endovascular stent grafting offers a potentially less invasive option for treatment of abdominal aortic
aneurysm. Clinical benefit has been demonstrated with respect to early parameters such as blood transfusion, return of
gastrointestinal function, and length of hospital stay. Endovascular repair, however, has been criticized on the basis of
inferior long-term outcome. Secondary procedures may be necessary to address durability issues such as migration,
high-pressure endoleak, graft limb thrombosis, and degeneration of the stent-fabric structure itself, issues that may
compromise the primary goal of aneurysm repair, protection from rupture.
Methods: Between 1996 and 2002, 703 patients underwent endovascular treatment of infrarenal abdominal aortic
aneurysm at The Cleveland Clinic Foundation. During this time, five devices were used: Ancure, AneuRx, Excluder,
Talent, and Zenith. Outcome was assessed with physical examination, lower extremity arterial studies, plain abdominal
radiography, and computed tomography at discharge, at 1, 6, and 12 months postoperatively, and annually thereafter.
Secondary procedures were defined as any procedure, exclusive of diagnostic angiography, performed after stent graft
implantation, directed at treatment of aneurysm-related events. Multivariable statistical techniques for censored data
(Cox proportional hazards modeling) were used to determine baseline parameters associated with need for secondary
procedures over follow-up, with calculation of hazards ratio (HR) and 95% confidence interval (CI).
Results: Patient follow-up averaged 12.2 11.7 months. Patient survival was 90% 1.4% at 1 year, 78% 2.6% at 2 years,
and 70% 3.8% at 3 years. Aneurysm rupture occurred in 3 patients (0.4%), accounting for rupture risk of 1.4% over the
first 2 years of follow-up (Kaplan-Meier method). Overall, 128 secondary procedures were required in 104 patients
(15%), with a cumulative risk of 12% 1.5% at 1 year, 24% 2.8% at 2 years, and 35% 4.4% at 3 years after stent graft
implantation. Among the secondary procedures, new stent grafts and extensions were placed in 34 patients (27%),
embolization of endoleak was performed in 33 patients (26%), and open surgical conversion was undertaken in 11
patients (9%). Periprocedural mortality of secondary procedures was 8% overall, but was 18% for patients undergoing
open surgical conversion. Multivariable modeling identified the date the procedure was performed (HR, 1.53 per
3-month period of study; CI, 1.22-1.92; P < .001) and aneurysm size (HR, 1.35 per centimeter of minor axis; CI,
1.13-1.60; P < .001) as independent predictors of need for secondary procedures.
Conclusions: Current endovascular devices are associated with a relatively high rate of complications over mid-term
follow-up, culminating in frequent need for secondary remedial procedures. With strict follow-up imaging compliance,
however, risk for rupture and aneurysm-related death remain exceedingly low. Newer technology may achieve improved
durability and a lower requirement for secondary procedures, while maintaining the minimally invasive nature of
presently available devices. (J Vasc Surg 2003;37:930-7.)
Endovascular abdominal aortic aneurysm (AAA) repair
provides substantial clinical benefit for the patient.1 The
physiologic insult is clearly reduced with endovascular tech-
niques compared with a traditional approach, culminating
in decreased use of the intensive care unit, diminished
length of hospital stay, and early return to normal activi-
ties.2 In contrast, longer term outcome may be inferior in
patients who receive stent -grafts, with a greater require-
ment for hospital readmission to treat device-related prob-
lems.3,4 The need for secondary procedures reached 33%
within 3 years of endovascular aneurysm repair in patients
entered into the EUROSTAR registry.5 Persistent en-
doleak, device migration, and limb thrombosis were com-
mon causes for these remedial procedures, approximately
one fourth of which were open surgical procedures and
three fourths were endovascular procedures.3
A variety of issues may underlie the low durability of
present endovascular devices. Some of these issues may
relate to anatomy of the aorta and iliac vessels, parameters
best assessed with precise anatomic measurements such as
those accessible from core laboratory data. Other concerns
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may derive from clinical variables such as demographic
parameters, aneurysm size, or brand of device implanted.
The present investigation was undertaken to characterize
the nature and frequency of secondary interventions after
endovascular aneurysm repair, with analysis of baseline
variables predictive of remedial interventions.
METHODS
Over 6 years ending in 2002, 703 patients underwent
endovascular repair of infrarenal AAA. Five devices were
used over this period: Ancure (Guidant, Menlo Park, Calif),
AneuRx (Medtronic/AVE, Santa Rosa, Calif), Excluder
(W. L. Gore, Flagstaff, Ariz), Talent (Medtronic/AVE),
and Zenith (Cook Inc, Bloomington, Ind). Among the
703 patients, 555 patients (79%) received treatment in
investigational device exemption (IDE) trials: 362 (51%) as
part of multicenter corporate-sponsored clinical evalua-
tions, and 193 (27%) under single-institution sponsor-
investigator IDE studies. The Institutional Review Board
of The Cleveland Clinic Foundation approved the study
protocols and the informed consent forms. Commercially
available devices were placed in the remaining 148 patients
(21%), and informed consent was obtained from each of
these patients. Patients who received Zenith devices were
categorized as those in whom devices were placed as part of
a multicenter clinical trial (pivotal and continuing access
phases, Zenith-MCT) and those who received treatment as
part of a sponsor-investigator IDE (Zenith-SIT). This sub-
division was deemed necessary because of the broadly dif-
fering anatomic eligibility criteria in the two subgroups.
The follow-up protocol was similar for patients in IDE
trials and patients who underwent implantation of com-
mercially available devices, representing the standard of
care for patients receiving treatment at the institution (Ta-
ble I). Preoperative helical computed tomography (CT)
was performed with 3 mm axial reconstruction. Angiogra-
phy and intravascular ultrasound studies were also per-
formed when measurements were deemed inaccurate on
the basis of CT scans, in the presence of suspected renal or
iliac occlusive disease, or when the endograft was placed as
part of a clinical trial that mandated these studies. Except in
patients with contraindications such as renal insufficiency
or history of severe allergy to contrast material, postopera-
tive CT scans included non-contrast-enhanced, contrast-
enhanced, and 3-minute to 5-minute delayed post-con-
trast-enhanced images. Delayed scans are included in our
imaging protocol to improve sensitivity for detecting en-
doleak, with careful comparison of sac appearance on pre-
contrast-enhanced scans and delayed scans.
Data were collected from a review of radiology imaging
reports and physician chart notes. Any significant discrep-
ancy between these two data sources prompted an interro-
gation of the source imaging studies. Outcome reporting
adhered to the standards outlined by the Ad Hoc Commit-
tee for Standardized Reporting Practices in Vascular Sur-
gery of The Society for Vascular Surgery/American Asso-
ciation for Vascular Surgery (SVS/AAVS).4 Late deaths
were classified as aneurysm-unrelated or aneurysm-related,
where aneurysm-related deaths included those deaths that
occurred as a result of aneurysm rupture or after any pri-
mary or secondary procedure directed at treating the aneu-
rysm or complications thereof.
Secondary procedures were defined as any subsequent
procedure, whether percutaneous or open surgical, related
to aneurysm repair or complications thereof. While proce-
dures performed because of wound complications were
tabulated for descriptive purposes, they were excluded from
statistical analysis.
Endoleak was classified on the basis of serial imaging
studies.5,6 CT findings, although most influential, com-
posed only one factor. Presumed type I leak observed on
CT scans was invariably followed up with angiographic
confirmation. A leak was considered type II when the
contrast collection was posterior or at the orifice of the
inferior mesenteric artery. Type II and IV endoleaks noted
only on an intraoperative or predischarge imaging study
were excluded from analysis. Leakage through enlarged
suture holes or fabric tears was classified as type III en-
doleak, as were defects related to separation of modular
components.7 An endoleak was suspected to be type III
when it directly abutted the graft fabric or was associated
with obvious disunion of components; half of these were
confirmed at angiography or at open surgical conversion.
Migration was defined with clinical and radiographic pa-
rameters, as suggested by the SVS/AAVS document on
endovascular reporting standards.4 Migration included
caudal movement of the proximal attachment site or cranial
movement of a distal attachment site. A device was consid-
ered to have migrated when at least 10 mm of movement
was noted relative to anatomic landmarks, when the patient
experienced symptoms, or when an intervention was un-
dertaken to treat migration, irrespective of distance. Aneu-
rysm shrinkage or growth was determined with a preproce-
dural CT scan performed 3 months or less before the date
of the procedure as the baseline. A predischarge imaging
study was used as the reference scan when a preoperative
study was not available. Size measurements were made on
the CT scan with the greatest minor sac dimension on any
Table I. Follow-up protocol comprising institutional standard of care
Item Timing
History and physical examination Preoperative; at discharge; 1, 6, 12 months; yearly thereafter
Four-view abdominal plain radiograph films* At discharge; 1, 6, 12 months; yearly thereafter
Helical CT scans Within 3 months of repair; at discharge; 1, 6, 12 months; yearly thereafter
*Before 1999, abdominal plain x-ray films were obtained in two planes alone, anteroposterior and lateral.
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axial image. Aneurysm shrinkage was defined as decrease of
5 mm or more in the minor dimension of the sac; enlarge-
ment was defined as increase of 5 mm or more in this
dimension.
The individual clinician responsible for the patient’s
care determined the need for secondary procedures. Cer-
tain clinical events mandated intervention, including post-
implant aneurysm rupture or symptomatic graft limb occlu-
sion. Most, however, were less catastrophic, and the need
for secondary intervention was subjective. Basic treatment
paradigms were, however, standard at the institution.
Treatment of types I and III endoleaks was always recom-
mended. Type II endoleak was treated when the aneurysm
sac was observed to enlarge over time. As well, patients with
type II leak received treatment when the aneurysm failed to
contract despite observation for more than 12 months after
the initial endovascular repair. Type II leak in patients with
a shrinking sac was not treated. Device migration was
treated when it was associated with a type I leak or when the
remaining length of sealing was deemed inadequate, usu-
ally when reduced to less than 10 mm.
Statistical analysis was performed with methods appro-
priate for censored data. Kaplan-Meier survival analysis was
used to express patient survival, freedom from aneurysm-
related death, and freedom from secondary procedures.
Freedom from such sentinel events as endoleak, device
migration, graft limb occlusion, and post-repair sac shrink-
age or enlargement were also expressed with Kaplan-Meier
curves. Cox analysis was used to evaluate time to secondary
procedure for specific baseline variables including proce-
dure date, patient demographic parameters, aneurysm size,
and procedural details such as brand of device implanted
and use of adjuvant procedures including placement of
renal or aortic stents, hypogastric embolization, and use of
iliac conduits for access. Hazard ratio (HR) was calculated,
as was 95% confidence interval (CI). Multivariable Cox
proportional hazards modeling was used to define indepen-
dent predictors of secondary procedures. Values are speci-
fied as mean  SD, except for Kaplan-Meier analysis, in
which data are expressed as mean  SE. Significance was
assumed at P  .05.
RESULTS
Patient ages ranged from 48 to 100 years (mean, 75 
8.1 years); 605 (86%) were men and 98 (14%) were women.
The diameter of the aneurysm sac averaged 54 10 mm in
minor dimension and 58  11 mm in major dimension.
With a 5.5 cm threshold for minor and major sac axis, 283
aneurysms (40%) and 391 aneurysms (56%), respectively,
would be considered large. Pperative mortality (30 days)
was 1.7% overall (12 patients), 1.0% in those undergoing
elective treatment (7 patients), and 19% in those undergo-
ing urgent treatment (5 patients). Of the 12 operative
deaths, 10 (83%) were procedure-related and occurred as a
result of perioperative medical complications, whereas 2
(17%) were device-related and occurred as a direct result of
complications from the device. Mean duration of follow-up
was 12.2  11.7 months (range, 0-65 months). Patient
survival was 90%  1.4% at 1 year, 78%  2.6% at 2 years,
and 70%  3.8% at 3 years (Kaplan-Meier method; Fig 1).
Aneurysm-related deaths, including deaths related to the
initial procedure, occurred in 12 patients (1.7%) and ac-
counted for 16% of 74 deaths. Risk for aneurysm-related
death was 2.7% 0.5% at 1 year and 3.6% 1.2% at 2 and
3 years postoperatively.
There were 24 graft limb occlusions in 20 patients
(2.8%). Risk for limb occlusion was 2.7%  0.7% at 1 year,
4.1%  1.2% at 2 years, and 5.5%  1.9% at 3 years after
repair (Fig 2). Late limb occlusion was rare; no new limb
occlusion was observed after 30 months. Migration was
noted in 25 patients (3.6%) and, unlike limb occlusion,
appeared to increase in frequency over longitudinal follow-
up. Examination of the Kaplan-Meier curve revealed low
risk for migration during the first year after stent graft
implantation, estimated at 1.0% 0.5% at 1 year but rising
to 12% 3.1% after 3 years of follow-up. Endoleak, of any
type and observed at any point after discharge, was docu-
Fig 1. Patient survival, expressed as all-cause mortality and aneu-
rysm-related death.
Fig 2. Freedom from migration or graft limb occlusion over
follow-up.
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mented in 162 patients (23.0%). At Kaplan-Meier analysis,
risk for endoleak was 30%  2.3% at 1 year, 42%  3.4% at
2 years, and 56%  5.5% at 3 years after implantation (Fig
3). Most endoleaks were type II (35%  3.2% at 2 years);
fewer were device-related (type I or III, 10%  2.6% at 2
years). Sac shrinkage of 5 mm or more occurred in 39% 
2.7% of patients at 1 year, 60% 3.2% of patients at 2 years,
and 68% 3.6% of patients at 3 years after aneurysm repair
(Fig 4). Sac enlargement was observed in 3.5%  1.0% of
patients at 1 year, 11%  2.5% of patients at 2 years, and
21%  4.5% of patients at 3 years after repair.
Three post-implantation aneurysm ruptures occurred,
4, 7, and 19 months after implantation, respectively, for a
rupture-free probability of 98.6%  0.9% at 2 years, ac-
counting for a 0.7% annualized linear risk for rupture.
Cause of rupture was thought to be displacement of an iliac
limb from its attachment site and sudden development of a
distal type I endoleak in 1 patient and disunion of a proxi-
mal extension cuff from the main body in a second patient.
Cause of rupture remains undefined in the third patient,
but occurred in an aortic pseudoaneurysm that developed
at the juxtaposition of the proximal aspect of a stent graft
and a previously placed renal stent. Among the three pa-
tients with aneurysm rupture, two underwent conversion
to open surgery, and 1 of these patients died periopera-
tively. The third patient underwent successful endovascular
insertion of a proximal aortic extension cuff.
Overall, 128 secondary procedures were performed
in 104 patients (15%). Among secondary procedures, 4
were directed at treatment of infectious groin wound
complications and were excluded from subsequent anal-
yses, leaving 124 procedures performed in a 100- patient
cohort available for hazard analysis. Cumulative risk for
secondary procedures was 12%  1.5% at 1 year, 24% 
2.8% at 2 years, and 35%  4.4% at 3 years of follow-up
(Fig 5). Eight deaths occurred as a result of secondary
intervention, for a periprocedural mortality rate of 6.3%.
In total, conversion to open surgical repair was required
in 12 patients (1.9%); 1 was immediate and was excluded
from further study, and the remainder were tabulated as
secondary procedures. Among the 11 patients in whom
the secondary procedure was conversion to open sur-
gery, 2 patients died (18%). There were six major indi-
cations for secondary procedures: endoleak (n  63),
endograft migration (n  13), graft limb occlusion (n 
24 in 19 patients), postoperative hemorrhage (n  12),
inadvertent partial or complete renal artery coverage
(n 8), and aneurysm rupture (n 3). Interventions for
each of these indications are listed in Table II. Of note,
among 34 type II endoleaks treated, 20 (59%) were
treated because of sac enlargement and 10 (29%) because
of failure to contract over more than 12 months of
observation. In the remaining 4 patients (12%), angiog-
raphy was performed because of suspected device-related
(type I or III) leak, but type II leak was found at
angiography and were embolized at that time.
Univariable analysis identified four baseline variables
associated with a significantly increased risk for subse-
Fig 3. Freedom from endoleak over follow-up.
Fig 4. Freedom from aneurysm sac shrinkage or growth, defined
by change 5 mm or more in diameter compared with baseline index
CT scan.
Fig 5. Freedom from secondary procedures over follow-up.
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quent, secondary procedures (Table III). Secondary pro-
cedures were more common in patients with larger major
and minor aneurysm sac axes, in patients who received a
large aortic stent because of proximal endoleak evident at
initial aneurysm repair, and in patients who received
treatment later in the course of the review. There were
no significant differences in risk for secondary proce-
dures according to brand of device (Fig 6). Multivariable
analysis identified two independent predictors of second-
ary procedures: date of primary operation (HR, 1.53;
95% CI, 1.22-1.92 per quarter; P  .001) and minor
aneurysm axis (HR, 1.35; 95% CI, 1.13-1.60 per centi-
meter; P  .001).
DISCUSSION
More than 25 years ago, Dr Juan Parodi first envisaged
endovascular techniques for repair of AAA after he ob-
served the morbidity and mortality of traditional open
surgical repair when performed in patients with compro-
mised medical status.8 Reasoning that morbidity was di-
rectly proportional to invasiveness of the intervention, Dr
Parodi developed a transfemoral technique for aneurysm
repair. Early on, however, durability was a problem. The
initial aorto-aortic devices did not include a distal stent.
Table II. Number of complications and nature of interventions performed
Complication Procedures*
Covered
stent†
Bare
stent
Embolization
(branch/sac)
Bypass or
thrombectomy
Surgical
conversion Other‡
Total
events
Endoleak
Type I proximal§ 17 10 3 4 (1) 17
Type I distal 3 3 3
Type II 34 1§ 33 (1) 131
Type III, disunion 4 4 6
Type III, microleak 5 1 4 10
Migration 25
Proximal neck 6 4 1 1 13
Distal attachment site 6 6 12
Limb occlusion 24 2 19 (1) 3 24
Hemorrhage 12 4 8 (1) 12
Wound infection 4 4 (1) 4
Post-implant sac rupture 3 1 2 (1) 3
Renal compromise 8 8 (2) 8
Distal embolization 2 2 2
Total 128 34 14 33 19 11 17 270
Numbers in parentheses represent periprocedural deaths, when they occurred.
*Total complications, excluding those that were not treated. Number exceeds number of patients; many patients had more than one complication and more
than one secondary procedure.
†Includes placement of aortic extension cuffs (10), iliac extension limbs (18), and new stent grafts (6).
‡Evacuation of hematoma with (4) or without (4) repair of artery, incision and drainage of groin wound (4), fasciotomy (3), toe amputation (2).
§Extension limb placed to occlude backflow from hypogastric artery into sac.
Patients with proximal type I endoleak due to device migration (13) are categorized under endoleak heading and do not appear again under migration.
Table III. Summary of univariable risk in secondary
procedures after endovascular aneurysm repair
Hazard
ratio
95% Confidence
interval P
Male 1.101 (0.60, 2.02) .76
Age (per year) 1.001 (0.98, 1.03) .95
Procedure date (by quarter) 1.549 (1.24, 1.94) .001
Minor sac axis 1.364 (1.15, 1.62) .001
Major sac axis 1.373 (1.16, 1.62) .001
Renal stent 0.946 (0.38, 2.33) .90
Aortic stent 2.928 (1.35, 6.36) .007
Hypogastric embolization 1.243 (0.66, 2.34) .50
Iliac conduit 1.027 (0.32, 3.25) .96
Device .32
AneuRx (n  203) 1.000 Reference
Ancure (n  63) 1.217 (0.53, 2.78)
Talent (n  39) 2.161 (0.99, 4.73)
Zenith-MCT (n  144) 1.824 (0.94, 3.54)
Zenith-SIT (n  181) 1.446 (0.82, 2.56)
Other devices (n  73) 1.572 (0.84, 2.96)
Fig 6. Freedom from secondary procedures by brand of device
implanted. Follow-up is truncated at 24 months because of small
numbers of uncensored patients at this time, with resultant in-
crease in standard error of the estimate.
JOURNAL OF VASCULAR SURGERY
May 2003934 Sampram et al
Distal type I endoleak developed over time, resulting in
recurrent pressurization of the aneurysm sac.9 Even when
later iterations used proximal and distal stents to affix the
stent graft to the aorta, late endoleak ensued in an unac-
ceptably great proportion of patients who received nonbi-
furcated devices.10
Traditional open surgical repair is associated with a
moderate degree of periprocedural morbidity but sets a
high standard for long-term durability. While selected re-
views document graft-related complications in as many as
10% of patients,11,12 more recent series attest to lower
long-term risks.13 The Cleveland Clinic 10-year experience
documented an extremely low risk for graft-related compli-
cations, approximating 0.4% in more than 1135 consecu-
tive patients undergoing elective open surgical infrarenal
aortic aneurysm repair.13 In fairness to endovascular aneu-
rysm repair, however, studies of traditional aneurysm sur-
gery may be criticized on the basis of less rigorous long-
term imaging follow-up.
In the present analysis of approximately 700 endovas-
cular procedures performed at a single institution over 6
years, secondary procedures were deemed necessary in a
high proportion of patients. With Kaplan-Meier analysis,
risk for a secondary remedial procedure was 35% within 3
years of implantation. It must be emphasized, however,
that most secondary procedures were percutaneous. Open
surgical conversion was rarely necessary. This feature may in
part account for the low rate of aneurysm-related death
after endovascular repair, estimated at 3.6% over a 3-year
follow-up, inclusive of initial perioperative deaths. More-
over, death from aneurysm rupture occurred in only 2 of
703 (0.3%) patients followed up for a mean of 1 year.
Univariable analysis enabled identification of three vari-
ables associated with increased risk for asecondary proce-
dures: date the procedure was performed, use of a large
aortic stent for proximal endoleak at implantation, and
aneurysm size (minor and major axes). Although the par-
ticular brand of device did not achieve statistical signifi-
cance as a predictor of secondary procedures, confidence
intervals for several of the devices, particularly the Talent
and Zenith-MCT, suggest that type II statistical error is
great. Of interest, only two variables, ie, procedure date and
aneurysm size, remained significant in the multivariable
model.
The subjectivity of secondary procedures is the main
limitation of our analysis. It is likely that physicians were
more apt to intervene to treat an endoleak, for instance,
when the aneurysm was large. Equally likely, however, is
the association between challenging anatomy and larger
aneurysm.14 The proximal aortic neck shortens as the an-
eurysm enlarges,15 increasing potential for migration and
type I endoleak. As the aneurysm enlarges, longitudinal
dimensions change concurrently.16 Angulation of the aor-
tic neck and tortuosity of the iliac arteries would also be
expected to correlate with aneurysm size. Had these ana-
tomic parameters been available for analysis in the present
study, they might have been found to underlie the associ-
ation between secondary procedures and sac diameter.
However, precise baseline anatomic measurements were
unavailable for most patients included in the study.
Increasing risk for endoleak over follow-up was ex-
pected for device-related endoleak, specifically type I and
III leaks. By contrast, the observation of increasing risk for
type II leak was not expected. In part, this finding can be
explained by the cumulative manner in which we chose to
express the data. As well, however, a few patients demon-
strated new type II endoleak that became evident many
months after endograft implantation. It is quite possible
that these leaks were present from the start but were of
sufficiently low flow to remain below the threshold of
detection with conventional CT technology. Over time,
some type II leaks may act in a manner reminiscent of
arteriovenous fistula, ie, flow increases with decreased out-
flow resistance and dilatation of the inflow channels.
The second independent predictor of secondary proce-
dures was related to chronology of the initial endovascular
repair. Patients who received treatment later in the course
of the review were at markedly increased risk for secondary
procedures. There are several potential explanations for this
finding, each of which relates to practice change over time.
The most obvious explanation centers on a time-related
change in the aggressiveness with which clinicians treated
such events as endoleak, aneurysm enlargement, and device
migration. As well, clinicians may have begun to treat more
anatomically challenging cases during the later years of
study. While it is tempting to ascribe time-related changes
in the distribution of endograft brands to increased require-
ment for secondary procedures, the multivariable design of
the analysis suggests that the effect of variations in other
practice-associated parameters was stronger than the effect
of the brand of device.
Studies of endovascular aneurysm repair have been
criticized with respect to failure to demonstrate true pro-
tection from rupture. Collin and Murie17 noted that the
observed rupture risk of 1% per year after endovascular
repair was not remarkably different from the natural history
of most small aneurysms followed up without intervention.
It is appealing to compare the results of the present study
with natural history studies to determine whether endovas-
cular aneurysm repair truly protects against rupture and
whether the method does so to an extent equivalent to that
of traditional open surgical repair. While comparisons be-
tween our own series and the two multicenter randomized
small aneurysm trials are neither statistically nor scientifi-
cally robust, some element of protection from rupture and
aneurysm-associated death appears to be conferred by en-
dovascular repair. The UK Small Aneurysm Trial docu-
mented death from rupture in 31 of 563 (5.5%) aneurysms
in the surveillance group over a mean of 8 years of follow-
up.18 This finding was apparent in spite of the relatively
small size of the aneurysms and the fact that in 62% of these
patients open surgical repair was ultimately necessary. Sim-
ilar observations were noted in the Aneurysm Detection
and Management Trial.19 Although 62% of patients in the
surveillance group also eventually required open repair,
2.6% risk for aneurysm-related death was evident over mean
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follow-up of 4.9 years, with observed 0.6% annual risk for
rupture. The present endovascular series documents mid-
term risks comparable with or better than those of the
randomized trials. Moreover, these results were achieved in
a population in which approximately half of the patients
had large aneurysms that would have excluded them from
the randomized small aneurysm trials. The relatively low
mid-term survival rate in our series is most likely related to
our policy of advocating endovascular repair for patients
with medical comorbid conditions and recommending
open surgical repair for younger, healthier patients.
In summary, endovascular aneurysm repair in its present
state appears to be associated with durability that is inferior to
that we have become accustomed to with traditional open
surgical techniques. Unlike open repair, endovascular repair is
associated with a relatively frequent requirement for secondary
procedures designed to address problems including endoleak,
migration, and limb thrombosis. Despite these problems, the
technology does appear to protect patients from aneurysm
rupture and aneurysm-associated death. Here is where the
goals of endovascular repair attain relevance. Above all, endo-
vascular methods must protect patients from aneurysm rup-
ture and aneurysm-related death, at least to the extent accom-
plished with standard surgical repair. As well, these results
should be achieved with a lesser degree of patient discomfort,
shorter hospital stay, and more rapid return to normal activi-
ties. While protection from rupture and death appear to be
attainable with presently available endovascular technology, a
high rate of secondary procedures may negatively affect pa-
tient satisfaction. We expect that introduction of newer, more
durable devices presently under development might diminish
the rate of secondary procedures after endovascular aneurysm
repair. Until then, it seems reasonable to limit use of stent graft
repair to those patients with compromised medical status and
inordinate operative risk or to those patients willing to accept
the follow-up imaging protocols and who acknowledge the
higher rate of secondary procedures that are part and parcel of
present technology.
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DISCUSSION
Dr Jean Panneton (Rochester, Minn). I really enjoyed
your paper. The one thing I wonder is, with this very poor
survival free of reintervention, less than 50% basically, I wonder,
does this have any impact on the way you provide informed
consent to the patients about to undergo an endovascular repair
of their abdominal aneurysm, the way you explain risks and
benefits and what they are going to expect in the following
years?
Dr Kenneth Ouriel. It certainly does, Jean. In fact, we limit
endovascular repair to those patients who can’t undergo an open
surgical procedure or to those younger, healthier patients who fully
understand that they may need to return for secondary procedures.
The primary operation is not going to be the final intervention in
many patients.
Dr Christopher K. Zarins (Palo Alto, Calif). I would like to
congratulate you on a truly remarkable large series with outstand-
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ing results. My question relates to the secondary procedures, and
the issues and the complications and adverse events that happened.
Those for the most part are technical issues: technical issues of
placing the device, migration, type 1 endoleak, inadequate fixa-
tion. You have such a large experience, I wonder if you could give
us a hint as to whether there is a learning curve. Are you better at
placing the devices? If you could place the device perfectly, could
you avoid those secondary procedures? Could you avoid the ad-
verse events? How much of this is really how well you place your
device and then come back later to fix it because you could have put
that extender cuff on at time zero, as you know. My question is, Is
there a learning curve, and can we do it better, or is this what we are
going to deal with?
Dr Ouriel. I wish I could say that there is a learning curve.
In fact, there might be a backward learning curve. In our
multivariable analysis, of the two factors that were predictive of
a secondary procedure, one was the time the procedure was
performed. Secondary procedures were not more frequent in
the early cases; rather, they were more common in our late cases.
There was certainly a practice change where we became more
aggressive at treating problems such as type II endoleaks. Even
with our newer devices, devices that are not yet approved for
use, secondary procedures are common. In fact, our best device
was the AneuRx, even though the differences were not statisti-
cally significant. I do not think we are going to see major
changes, at least with the devices that we have now. Durability
issues, migration, endoleaks, and limb occlusions are problems
that will only be solved with the newer, truly more novel
technologies.
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